European Journal of Cancer
Volume 43, Issue 15 , Pages 2235-2241 , October 2007

Mastering chemotherapy dose reduction in elderly cancer patients

Received 9 March 2007 ,Revised 25 June 2007 ,Accepted 27 June 2007.

References 

  1. Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet. 2003;42:1213–1242
  2. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt). 2000;14:221–227
  3. De VV, Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back moving forward – the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987;47:5810–5824
  4. Bonadonna G, Valagussa P. Dose–response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10–15
  5. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–1288
  6. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control. 2001;8:1–25
  7. Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy?. Cancer. 2003;97:1107–1114
  8. Extermann M, Aapro M, Bernabei RB, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–252
  9. Fletcher AE, Price GM, Ng ESW, et al. Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial. Lancet. 2004;364:1667–1677
  10. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  11. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453
  12. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258–270
  13. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34
  14. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet. 1986;11:223–235
  15. Loadman PM, Bibby MC. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet. 1994;26:486–500
  16. Slaets JPJ. Vulnerability in the elderly: frailty. Med Clin North Am. 2006;90:593

PII: S0959-8049(07)00511-4

doi: 10.1016/j.ejca.2007.06.013

European Journal of Cancer
Volume 43, Issue 15 , Pages 2235-2241 , October 2007

Article Tools